SCHEMBL710758

SCHEMBL710758

CCSc1ccc(C=O)cc1

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.58
GSK3B P49841 1/20 0.50
ALDH3A1 P30838 1/20 0.48
ALDH1A3 P47895 1/20 0.48
CYP2A6 P11509 3/20 0.46
SLC6A4 P31645 5/20 0.42
MAOA P21397 1/20 0.42
HPGD P15428 3/20 0.42
TDP1 Q9NUW8 2/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
MAPT P10636 2/20 0.42
NPSR1 Q6W5P4 1/20 0.42
TYR P14679 1/20 0.41
CYP2A13 Q16696 1/20 0.41
HSD17B10 Q99714 1/20 0.41
ALDH5A1 P51649 1/20 0.41
ABAT P80404 1/20 0.41
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8595279 0.83 ALDH1A1 (0.54) ALDH1A1ALDH3A1ALDH1A3CYP2A6MAOA
SCHEMBL346860 0.80 SLC6A4 (0.56) ALDH1A1GSK3BSLC6A4MAOANPC1
SCHEMBL3405047 0.79 ALDH1A1 (0.50) ALDH1A1ALDH3A1ALDH1A3CYP2A6MAOA
SCHEMBL5198346 0.77 ALDH1A1 (0.50) ALDH1A1GSK3BSLC6A4MAOATDP1
SCHEMBL2622606 0.77 GSK3B (0.46) GSK3BSLC6A4MAOANPC1RAB9A
SCHEMBL18885132 0.77 ALDH1A1 (0.52) ALDH1A1ALDH3A1ALDH1A3CYP2A6HPGD
SCHEMBL10424504 0.77 ALDH1A1 (0.52) ALDH1A1ALDH3A1ALDH1A3CYP2A6HPGD
SCHEMBL7323727 0.77 GSK3B (0.46) ALDH1A1GSK3BSLC6A4MAOANPC1
SCHEMBL20319851 0.77 GSK3B (0.46) ALDH1A1GSK3BSLC6A4MAOANPC1
SCHEMBL10656224 0.77 ALDH1A1 (0.52) ALDH1A1ALDH3A1ALDH1A3CYP2A6MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5298630-A Reacting 2-alkylthiobenzaldehyde derivative with halo compound SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) 1994-03-29 US claimed
EP-0572712-A2 Processes for producing 2-substituted benzo(beta)thiophene SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) 1993-12-08 EP claimed
JP-1100155-A None JP disclosed
US-20240300934-A1 COMPOUNDS FOR MODULATING MYCOBACTERIUM TUBERCULOSIS RESPONSE RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY 2024-09-12 US disclosed
WO-2023283608-A1 COMPOUNDS FOR MODULATING MYCOBACTERIUM TUBERCULOSIS RESPONSE TRUSTEES OF TUFTS COLLEGE (US) 2023-01-12 WO disclosed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
EP-2814814-B1 IMIDAZOLYLKETONE DERIVATIVES ASD ALDOSTERONE SYNTHASE INHIBITORS HOFFMANN LA ROCHE (CH) 2019-05-08 EP disclosed
WO-2018042342-A1 1,2,3-BENZOTRIAZOLE DERIVATIVES AS ROR GAMMA T MODULATORS GLENMARK PHARMACEUTICALS S.A. (CH) 2018-03-08 WO disclosed
US-9884832-B2 Inhibitors targeting drug-resistant influenza A THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2018-02-06 US disclosed
US-9464058-B2 Imidazolylketone derivatives HOFFMANN-LA ROCHE INC. (US) 2016-10-11 US disclosed
US-20150191439-A1 INHIBITORS TARGETING DRUG-RESISTANT INFLUENZA A NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-07-09 US disclosed
EP-0328669-A1 CHALCONE DERIVATIVE COMPOUNDS NIPPON OIL AND FATS COMPANY, LIMITED (JP) 1989-08-23 EP disclosed
EP-0328668-A1 NONLINEAR OPTICAL MATERIAL NIPPON OIL AND FATS COMPANY, LIMITED (JP) 1989-08-23 EP disclosed
JP-H01100155-A CINNAMOYLALKANE DERIVATIVE COMPOUND NIPPON OIL & FATS CO LTD 1989-04-18 JP disclosed
US-4517192-A 6-Alkyl-5-[4-(alkylsulfinyl or alkylsulfonyl)phenyl]-2(1H)-pyridinones and their use as cardiatonics STERLING DRUG INC. (US) 1985-05-14 US disclosed
US-4396553-A Tetrahydronaphthalene and indane compounds useful as anti-tumor agents HOFFMANN-LA ROCHE INC. (US) 1983-08-02 US disclosed
US-4087549-A Sulphonic acid containing indenyl derivatives MERCK & CO., INC. (US) 1978-05-02 US disclosed
US-3946028-A HYPOTENSIVE AGENTS, CORONARY VESSEL DILATORS BAYER AKTIENGESELLSCHAFT (DT) 1976-03-23 US disclosed
US-3946027-A HYPOTENSIVE AGENTS, CORONARY VESSEL DILATORS BAYER AKTIENGESELLSCHAFT (DT) 1976-03-23 US disclosed
US-3943140-A HYPOTENSIVE, VASODILATION BAYER AKTIENGESELLSCHAFT (DT) 1976-03-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150191439-A1 INHIBITORS TARGETING DRUG-RESISTANT INFLUENZA A HAVCR2, HDLBP, HSP90B1 ALDH1A1 3831/4885GSK3B 942/4885ALDH3A1 4000/4885
US-20240300934-A1 COMPOUNDS FOR MODULATING MYCOBACTERIUM TUBERCULOSIS RESPONSE IFNG, NFATC1, RELA ALDH1A1 1559/4885GSK3B 2225/4885ALDH3A1 2271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.